All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Specific immune responses after BNT162b2 mRNA vaccination and COVID-19 infection

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3A_____%2F23%3AN0000003" target="_blank" >RIV/60162694:_____/23:N0000003 - isvavai.cz</a>

  • Alternative codes found

    RIV/61383082:_____/23:00001287 RIV/00216208:11110/23:10470920

  • Result on the web

    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619853/" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619853/</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.3389/fimmu.2023.1271353" target="_blank" >10.3389/fimmu.2023.1271353</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Specific immune responses after BNT162b2 mRNA vaccination and COVID-19 infection

  • Original language description

    Although vaccines against COVID-19 are effective tools in preventing severe disease, recent studies have shown enhanced protection after vaccine boosters. The aim of our study was to examine the dynamics and duration of both humoral and cellular immune responses following a three-dose regimen of the BNT162b2 mRNA vaccine. In a longitudinal prospective study we enrolled 86 adults who received the BNT162b2 vaccine, 35 unvaccinated individuals with a history of mild COVID-19 and a control group of 30 healthy SARS-CoV-2 seronegative persons. We assessed the SARS-CoV-2-specific T cell responses and IgG production up to 12 months post the third BNT162b2 dose in 24 subjects. The vaccinated group had significantly higher IgG antibody levels after two doses compared to the convalescent group (p<0.001). After the third dose, IgG levels surged beyond those detected after the second dose (p<0.001). Notably, these elevated IgG levels were maintained 12 months post the third dose. After two doses, specific T cell responses were detected in 87.5% of the vaccinated group. Additionally, there was a significant decrease before the third dose. However, post the third dose, specific T cell responses surged and remained stable up to the 12-month period. Our findings indicate that the BNT162b2 vaccine induces potent and enduring humoral and cellular responses, which are notably enhanced by the third dose and remain persistant without a significant decline a year after the booster. Further research is essential to understand the potential need for subsequent boosters.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30102 - Immunology

Result continuities

  • Project

    <a href="/en/project/VI04000078" target="_blank" >VI04000078: The development of a comprehensive assessment methodology for the immune preparedness of members of the security and protective services responding to the COVID-19 pandemic</a><br>

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2023

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Frontiers in immunology

  • ISSN

    1664-3224

  • e-ISSN

    1664-3224

  • Volume of the periodical

    14

  • Issue of the periodical within the volume

    17.10.2023

  • Country of publishing house

    CH - SWITZERLAND

  • Number of pages

    6

  • Pages from-to

    nestrankovano

  • UT code for WoS article

    001093015100001

  • EID of the result in the Scopus database